Company intelligence / Profile preview

TeamSparta

Ownership: Private
Development stage: Other

Overview

Sparta Biomedical has developed a proprietary chemically engineered cartilage platform called Galene, designed to immediately replicate the physical properties of native human hyaline cartilage. Their lead product, Ormi™, combines Galene with a titanium base and has received Breakthrough Device designation. The technology aims to provide immediate pain reduction and restore range of motion in patients with osteoarthritis or cartilage defects. Clinical results are not yet published but preclinical data suggest rapid functional restoration compared to traditional regenerative approaches.

Therapeutic areas: Rheumatology
Modalities: DeviceBiomaterial implant
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on TeamSparta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TeamSparta.

Explore the full profile